945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)

Journal article

Open access

Peer reviewed

R E O'Cearbhaill, A Wolfer, P Disilvestro, D M O'Malley, P Sabbatini, L Shohara, P O Schwarzenberger, T Ricciardi, M Macri, A Ryan, …

Annals of oncology, Vol.29(suppl_8)

10/01/2018

Files and links (1)

url

https://doi.org/10.1093/annonc/mdy285.153View

Published (Version of record) Open

6 Record Views

Title: 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
Creators: R E O'Cearbhaill - Memorial Sloan Kettering Cancer Center
A Wolfer - University of Lausanne
P Disilvestro - Women & Infants Hospital of Rhode Island
D M O'Malley - The Ohio State University
P Sabbatini - Memorial Sloan Kettering Cancer Center
L Shohara - Ludwig Cancer Research
P O Schwarzenberger - Ludwig Cancer Research
T Ricciardi - Ludwig Cancer Research
M Macri - Ludwig Cancer Research
A Ryan - Ludwig Cancer Research
R R Venhaus - Ludwig Cancer Research
J K Bryan - Research, Novella Clinical, Seattle, WA, USA
P Wong - Memorial Sloan Kettering Cancer Center
K Homicsko - University of Lausanne
L Kandalaft - University Hospital of Lausanne
S Rusakiewicz - University Hospital of Lausanne
A Harari - University Hospital of Lausanne
B J Monk - Creighton University
G Coukos - University Hospital of Lausanne
Publication Details: Annals of oncology, Vol.29(suppl_8)
Publisher: Oxford University Press
Identifiers: 991005968877602656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article